Sign in to fuzzto save your conversations, follow your research and come back anytime.
Caplin Point Laboratories
SectorHealthcare
Caplin Point Laboratories Limited is an Indian pharmaceutical company founded in 1990. It develops, produces, and markets generic formulations and branded products globally. The company has manufacturing facilities in India and serves markets in Latin America, Africa, the USA, and the European Union. Caplin Point specializes in various pharmaceutical formulations, including injectables, tablets, capsules, and syrups. The company has expanded through acquisitions, partnerships, and investments in subsidiaries. It has a strong presence in emerging markets and has entered regulated markets like the USA. Caplin Point has invested in research and development, including API development and clinical research. The company has also ventured into e-commerce and has been expanding its product portfolio and manufacturing capabilities.
In the news
Caplin Point Lab breaks consolidation, targets ₹3,230
3 Pharma Stocks in Focus: GMP Clearances & GSK's mRNA Flu Vaccine
Caplin Point shares fall 2.38% after USFDA issues 10 observations
Caplin Point Labs Q1 profit jumps 17.5% to ₹179.6 cr
Caplin Point Lab hits 52-week high at ₹2,405.4, stock surges 20% in 5 days
ICICI Securities recommends Caplin Point buy amid ₹27,048 cr FII outflows
Caplin Point Labs Q4 profit jumps 19.32% to ₹170.11 cr
Caplin Point shares surge 9% on strong Q4 results, profit up 19%
Caplin Point Acquires 10 ANDAs Worth $473M to Strengthen US Portfolio
Company insights, generated from the most recent coverage.
Oct 12 fall of 2.35% had no company-specific trigger — latest filing was Sept 28. This is profit-booking and valuation reset, with aggregator analyst targets near ₹2,320 sitting below the market price.
BSE and NSE queried a Sept 24-25 volume spike; company said all disclosures were made and the spike was market-driven. Heavy turnover followed by a falling price points to institutional repositioning rather than fresh news.
Cash conversion is lagging growth: Q1 FY27 operating cash flow fell to ₹95 Cr from ₹118 Cr, leaving only ₹40 Cr free cash after ₹55 Cr capex. For a stock at a premium multiple, weak FCF is a sentiment drag.